The first semaglutide slimming pill is also available in Europe: 17%It can achieve an average weight loss of 17%

The European Commission has approved the first oral semaglutide medication for weight loss, marking a major advancement in treating obesity and overweight conditions. The drug, produced by Novo Nordisk, is available in a daily dose of 25 milligrams and offers a convenient alternative to weekly injections. This approval comes after extensive clinical trials demonstrated its effectiveness in helping patients achieve substantial weight loss. According to data from the OASIS 4 study, patients taking the medication alongside a reduced-calorie diet and physical activity lost an average of 17% of their body weight, compared to just 2.7% among those receiving a placebo. Additionally, approximately one-third of participants were classified as "early responders," losing up to 22% of their body weight within 64 weeks. The medication works by targeting what medical professionals refer to as "food noise", a persistent mental distraction related to eating that can significantly impact quality of life. Dr. Annamaria Colao, professor of Endocrinology at the University of Naples Federico II, noted that the formulation has shown manageable safety even when used with common medications such as oral contraceptives and statins. She emphasized that the drug's ability to reduce food-related distractions could help individuals regain control over their eating habits and improve overall well-being. Beyond weight loss, the drug also shows promise in reducing cardiovascular risks. Data from the SELECT study revealed a 20% reduction in the risk of major adverse cardiac events, including heart attacks and strokes. Dr. Paolo Sbraccia, professor of Internal Medicine at the University of Rome Tor Vergata and president of the IBDO Foundation, highlighted the importance of this treatment for patients who are motivated to manage their weight but have lacked effective options. He stated that the new medication allows clinicians to treat excess weight and obesity more effectively while lowering the risk of associated complications. The medication is intended for adults with obesity, defined as a body mass index (BMI) of 30 or higher, and for those with overweight, BMI of 27 or higher, who have at least one associated complication. It represents a significant milestone for public health, offering a simple and accessible solution for managing a complex condition. Jens Pii Olesen, general manager of Novo Nordisk Italy, expressed satisfaction with the results, stating that the approval brings them closer to meeting the unmet needs of individuals struggling with overweight or obesity. He described the approval as a concrete response to one of today’s key public health challenges. This approval marks a turning point in how obesity is managed, transforming a once-intensive process into a routine part of daily life. With the availability of an oral option, patients can now take control of their weight management efforts through a straightforward regimen. As research continues to explore the long-term benefits and potential side effects of the medication, healthcare providers and patients alike look forward to the possibilities this new treatment presents. The approval of semaglutide as an oral therapy underscores a growing commitment to innovation in addressing obesity, a condition that affects millions and carries serious health implications.